Lantern Pharma has established an artificial intelligence Center of Excellence and Advanced Agentic Labs in Bengaluru, India, positioning the facility as the company’s global scale-up center for its proprietary RADR AI platform. The strategic move aims to industrialize AI-enabled drug discovery capabilities at a global scale while maintaining a cash-neutral financial impact during early deployment phases.
The Bengaluru hub will expand computational capacity, technical talent, and continuous development cycles to support both Lantern’s internal oncology pipeline and a growing roster of pharmaceutical and academic collaborators. This expansion is expected to accelerate development of specialized large language and quantitative models for molecular assessment, optimization, and de novo drug generation. The company plans to use this enhanced infrastructure to eventually expand beyond oncology into additional disease areas.
Lantern Pharma’s RADR AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials. The company’s current clinical-stage pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations. The new Indian facility represents what the company describes as a strategic inflection point in its evolution toward industrialized AI drug discovery.
The announcement was made through AINewsWire, a specialized communications platform focused on artificial intelligence advancements that is part of the Dynamic Brand Portfolio at IBN. Additional information about the company is available in its newsroom at https://ibn.fm/LTRN. The establishment of this AI center comes as biotechnology companies increasingly leverage computational approaches to streamline drug development processes and bring precision therapies to market more efficiently.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Lantern Pharma Establishes AI Center of Excellence in India to Scale Drug Discovery Platform.